x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

cc: Life Science Podcast

How will AI, CRISPR, CGT and other new technologies impact life science? I"m following my curiosity. Follow along with me. cclifescience.substack.com

science life sciences

All Episodes

28:02

Mining the Microbiome for Possibilities

cc: Life Science Podcast ·

2023/12/20

When it comes to chemical reactions, if you can imagine it, somewhere out there a microbe is already doing it. This was something we used to say in graduate school. The challenge is finding that microbe among the billions that exist in environments all around us.Surehka Karudapuram is the VP, Commercial Operations at Isolation Bio where they are helping researchers solve that needle in a haystack problem. In this episode we talked about the what, the how and the why.Check this out:Isolation Bio

en

53:04

Helping Cancer Patients Navigate the Journey Based on...

cc: Life Science Podcast ·

2023/12/13

Rochelle Prosser is the founder and president of Orchid Healthcare Solutions, the company she created to consolidate cancer treatment information and improve access to that information. We discussed the difficulties in navigating healthcare systems and the importance of having comprehensive, scientifically-driven resources for cancer patients and caregivers.Rochelle is a neurotrauma critical care nurse with 30 years of experience. She has had her own journey in healthcare and felt the impact of

en

34:39

Accelerating Drug Discovery with Virtual Screening

cc: Life Science Podcast ·

2023/11/29

Tom Pesnot is the Head of Medicinal Chemistry at Concept Life Sciences. I invited him to talk about AI and virtual screening in the drug discovery process.By way of review, Tom laid out the overall process of discovery. One needs to identify a target whose activity can be modulated in a way that is of course, relevant to the disease of interest. Most often we are trying to stop a protein from carrying out its normal function. Then we are looking for hits — interactions of candidate compounds with

en

33:27

Crafting Narratives with AI Based on Data

cc: Life Science Podcast ·

2023/11/08

Note: For this episode, because we are discussing the narrative capabilities of AI, I asked ChatGPT to write a summary based on the transcript of our conversation. I enjoy doing these interviews and consider myself a decent writer. However, it takes a lot of time each week to write a summary that I find minimally satisfying and acceptable. You deserve better and I can put my efforts to better use elsewhere or upgrading the whole experience here. I did lightly edit this to make it sound as if I could

en

35:58

Cultivating Climate Solutions with Microbial Cover Crops

cc: Life Science Podcast ·

2023/10/25

Barry Goldman, founder and CSO of Pluton Biosciences introduces the concept of microbial cover crops as a new and innovative approach to improving soil health and sustainable agriculture. A plant cover crop e.g. alfalfa, is typically grown in the off-season and plowed back into the field to enrich the soil before the actual crop is planted. Barry and his team set out to see whether some bacteria can do this, particularly around nitrogen fixation, adding ammonia to the soil from the atmosphere. He

en

28:11

What is a Liaison Research Organization?

cc: Life Science Podcast ·

2023/10/11

Dr. Antonio Tito is the Founder and CEO of rEthix in Houston, Texas. rEthix is the world’s first Liaison Research Organization (LRO) facilitating clinical trials in Mexico and Latin America.A search of clinicaltrials.gov shows that several large pharma companies are currently running trials in Mexico. rEthix is leveraging the ICH (International Council for Harmonisation) guidelines to run these trials in Mexico and use that data to support IND-enabling studies in the US. The ICH sets the guidelines

en

48:09

Thinking Differently About Combating Antibiotic...

cc: Life Science Podcast ·

2023/09/06

A new antimicrobial cured mice infected with bacteria deemed nearly “untreatable” in humans — and resistance to the drug was virtually undetectable.The World Health Organization has identified antimicrobial resistance as a major threat to global health. Bacterial resistance to antibiotics only increases over time. The problem is made worse by the fact that the incentives to discover and develop new antibiotics aren’t aligned with the pharmaceutical industry model. It takes billions of dollars to

en

35:15

Valuing Startups: A Real Option Model for Binary...

cc: Life Science Podcast ·

2023/08/30

I enjoyed this conversation with Adrian Rubstein, founder of Ax3.bio, as he opened my eyes to different approaches to valuing startups. Make sure you listen to the full episode. I promise you will learn something valuable.Adrian inspired me to do some research on my own. So any errors in this description are mine. (A little knowledge is a dangerous thing). But let’s try anyway…Most biotech companies are destined to fail. That’s no secret. Biology is full of uncertainty. Outcomes in biotech are

en

28:55

Advancing Precision Medicine in a Co-op Model

cc: Life Science Podcast ·

2023/08/16

I’m not a healthcare expert by any stretch except as an occasional recipient of care that I’m generally happy with.As an observer, however, our system, in the US at least, looks fractured. Many people don’t have access to care. At the same time, significant innovations are racing along, but many physicians are likely too overwhelmed to incorporate new technologies like genomic testing. It probably feels like jumping on a moving train. Does that further increase the disparities in the system? How can

en

33:21

Identifying Bacteria in Clinical Samples by Raman...

cc: Life Science Podcast ·

2023/08/02

For a patient with sepsis (an infection in the blood), the chance of survival decreases by 7-10% every hour. It’s important to quickly identify what bacteria are present and which antibiotics might be effective.Typically, there are very few bacteria in the blood. Culturing bacteria from a sample can take 12-24 hours and then one needs to test for drug susceptibility. Speeding up this process would save a lot of lives.Jen Dionne and her collaborators at Stanford are working on this problem using

en

42:49

The Importance of Science Communication in Public Health

cc: Life Science Podcast ·

2023/07/19

Science is pretty cool. We can send astronauts to the moon, watch tv on a phone that fits in our pocket or rid the world of smallpox. It makes problems go away so well, it’s as if they no longer exist. That can be a problem in itself.In this episode, I talked to Dr. Rodney Rohde (Doc R) about the role of science communication in public health. To get warmed up, we had a conversation about the state of infectious diseases like rabies and MRSA (Methicillin-resistant Staph aureus).The incidence of

en

34:48

Pharmacoeconomics: Where do the numbers come from?

cc: Life Science Podcast ·

2023/07/12

What is the cost to an employer of chronic presenteeism, where a person is well enough to go to work but isn’t really productive? What is the dollar value to a patient of being married in terms of health outcomes? How do you figure that out? There are so many factors to consider. When we read that condition [fill in the blank] accounts for X dollars of lost productivity per year, I always wonder, “where does that number come from and who came up with it?” In this episode, we find out.Lemar Ashar, a

en

31:37

AI in High Content Analysis

cc: Life Science Podcast ·

2023/06/21

I went to SLAS this spring to talk to old friends, meet some new ones and learn whatever I could. I met Maggie Vantangoli, the Director of Marketing at Araceli Biosciences in their booth where we chatted about the use of artificial intelligence (AI) for high content analysis (HCA) in drug discovery and development. She was kind enough to join me on this podcast and fill in the (large) holes in my knowledge of cell biology. HCA is basically automated microscopy and analysis of fluorescently-stained

en

30:12

Wrangling Multiple AI Projects

cc: Life Science Podcast ·

2023/05/17

According to their website, IQVIA holds over 60 petabytes (60 million gigabytes) of proprietary data used to provide insights and inform decisions across the healthcare industry. Think market dynamics around a disease, demographics and site selection for clinical trials or pricing for a new therapeutic.How does one pull the insights out of that mountain of data? Chris Steel was brought on board to drive AI and machine learning into all their products, standardize on platforms and unify the message

en

43:13

Do You Know About Design of Experiments (DoE)?

cc: Life Science Podcast ·

2023/05/03

Early in our education about science, we learn that to understand what is happening in a system, we can only change one variable at a time. That seems reasonable. By doing that, we can see which variables matter. It turns out that this is not only slow, but in biology, possibly incomplete. If there is a two-factor interaction (not uncommon) you will miss it. The good news is that it’s possible to analyze many variables at the same time and understand which ones matter. One can also see the

en

32:15

The Difficulties of Diagnostic Development

cc: Life Science Podcast ·

2023/04/19

Because most of us have likely had a Covid test done in the last few years, you might think that getting diagnostics to market is a straightforward proposition. But you’d be wrong. The reason is that even if you have a clinically proven test, there are no guarantees that someone will pay for that test. Further, there is no standard by which diagnostics are evaluated that leads to reimbursement. Hannah Mamuszka is the CEO at Alva10. She explained to me the market dynamics around developing new

en

24:45

Manufacturing Drugs in Zero Gravity

cc: Life Science Podcast ·

2023/04/06

Imagine a capsule whizzing by some 200 miles overhead. It’s just big enough to hold a medium size dog (curled up and sleeping) but there is no life onboard. Instead, there is an automated laboratory designed for manufacturing pharmaceuticals. That is the vision of Varda Space Industries. Do they really envision a future where drugs are manufactured in space at scale? Yes. I talked to Mark Herbert, VP of Biopharma Business Development at Varda, about their plans. My two big questions were 1. What is

en

30:54

De-extinction: The Why and the How

cc: Life Science Podcast ·

2023/03/29

My first reaction when I heard that George Church wanted to bring back the wooly mammoth was, “Uh, why don’t we stop trashing the environment and save the species we have left?” Later on, I learned that I may have missed the point. It turns out that as engineers of the environment, wooly mammoths might enhance the carbon storage capacity of the tundra and help us all chill out a bit (slow climate change). That covers part of the why question but not all of it. This is a BIG science project so there

en

29:50

Stem Cell Expansion Technologies

cc: Life Science Podcast ·

2023/03/22

Growing primary cells in 2D on plastic surfaces is not a good representation of the 3D environment of the body, regardless of your purpose. Cells grown in a dish eventually run out of room. They need to be disrupted and seeded onto new plates at a lower density. Then they run out of time. They just get tired and stop dividing. TBH, some days, I feel the same way.If these challenges can be overcome, we can, in addition to growing larger quantities of cells for investigation or production, learn a lot

en

33:14

Clinical Proteomics: What Does the Future Hold?

cc: Life Science Podcast ·

2023/03/08

When will we get to a place of reliable protein biomarkers as predictors or indicators of disease? Ole Vorm is a founder and director at Evosep, producing separation products between the patient sample and a mass spectrometer.What is the state of those analyses and what are the obstacles yet to be overcome? The first obstacle in terms of the proteome itself is that in any sample - urine, blood etc.- there are a few abundant proteins that represent the bulk of the material. It’s likely that the

en

76 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter